Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation to the 33rd edition of the annual J.P. Morgan Healthcare Conference which will be held from 12 to 16 January 2015 in San Francisco.
The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors.
Cardio3 BioSciences will meet with potential investors and explain to them its on-going development programs and strategic vision for the future.
Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “2014 was rich in events for our company. We made significant progress in the European Phase III clinical trial of C-Cure® and our strategic development was strengthened by an enlarged collaboration with Mayo Clinic and the acquisition of CorQuest Inc. The J.P. Morgan Healthcare Conference is an excellent opportunity to present Cardio3 BioSciences’ potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors.”
